These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31812127)

  • 1. Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial.
    Schmitz B; Dimova S; Zhang Y; Chellun D; De Backer M; Gasalla T
    Epilepsy Res; 2020 Jan; 159():106220. PubMed ID: 31812127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy.
    Ben-Menachem E; Grebe HP; Terada K; Jensen L; Li T; De Backer M; Steiniger-Brach B; Gasalla T; Brock M; Biton V
    Epilepsia; 2019 Dec; 60(12):2437-2447. PubMed ID: 31755090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lacosamide in patients with epilepsy of cerebrovascular etiology.
    Rosenow F; Brandt C; Bozorg A; Dimova S; Steiniger-Brach B; Zhang Y; Ferrò B; Holmes GL; Kälviäinen R
    Acta Neurol Scand; 2020 Jun; 141(6):473-482. PubMed ID: 32068241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed temporal lobe epilepsy: Post hoc analysis of a randomized, double-blind trial.
    Terada K; Kubota Y; Dimova S; Elmoufti S; Floricel F; Chellun D; O'Brien TJ
    Seizure; 2023 Nov; 112():62-67. PubMed ID: 37769545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.
    Baulac M; Rosenow F; Toledo M; Terada K; Li T; De Backer M; Werhahn KJ; Brock M
    Lancet Neurol; 2017 Jan; 16(1):43-54. PubMed ID: 27889312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.
    Trinka E; Ben-Menachem E; Kowacs PA; Elger C; Keller B; Löffler K; Rocha JF; Soares-da-Silva P
    Epilepsia; 2018 Feb; 59(2):479-491. PubMed ID: 29369348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double-blind study.
    Baulac M; Patten A; Giorgi L
    Epilepsia; 2014 Oct; 55(10):1534-43. PubMed ID: 25109239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.
    Powell G; Saunders M; Marson AG
    Cochrane Database Syst Rev; 2014 Feb; (2):CD007124. PubMed ID: 24488654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.
    Powell G; Saunders M; Rigby A; Marson AG
    Cochrane Database Syst Rev; 2014 Dec; (12):CD007124. PubMed ID: 25470302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.
    Powell G; Saunders M; Marson AG
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007124. PubMed ID: 20091617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.
    Powell G; Saunders M; Rigby A; Marson AG
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD007124. PubMed ID: 27933615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of adjunctive lacosamide in Chinese and Japanese adults with epilepsy and focal seizures: A long-term, open-label extension of a randomized, controlled trial.
    Inoue Y; Liao W; Wang X; Du X; Tennigkeit F; Sasamoto H; Osakabe T; Hoshii N; Yuen N; Hong Z
    Epilepsy Res; 2021 Oct; 176():106705. PubMed ID: 34246118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
    Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
    Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, multicenter, noninterventional study in Taiwan to evaluate the safety and tolerability of lacosamide as adjunctive therapy for epilepsy in clinical practice.
    Wu T; Chuang YC; Huang HC; Lim SN; Hsieh PF; Lee WT; Cheng MY; Tsai MH; Jou SB; Chang CW; Hsieh HY; Du X; Hellot S; McClung C; Hung C
    Epilepsy Behav; 2020 Dec; 113():107464. PubMed ID: 33152580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.
    Brodie MJ; Perucca E; Ryvlin P; Ben-Menachem E; Meencke HJ;
    Neurology; 2007 Feb; 68(6):402-8. PubMed ID: 17283312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.
    Nevitt SJ; Marson AG; Tudur Smith C
    Cochrane Database Syst Rev; 2019 Jul; 7(7):CD001911. PubMed ID: 31318037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study.
    Wechsler RT; Li G; French J; O'Brien TJ; D'Cruz O; Williams P; Goodson R; Brock M;
    Epilepsia; 2014 Jul; 55(7):1088-98. PubMed ID: 24915838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy.
    Farkas MK; Makedonska I; Beller C; Bourikas D; de la Loge C; Dimova S; Floricel F; McClung C; Moseley B; Therriault S; Pina-Garza JE
    Epilepsy Behav; 2024 Oct; 159():109989. PubMed ID: 39216464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and tolerability of lacosamide monotherapy in patients with epilepsy: Results from a multicenter, open-label trial.
    Ben-Menachem E; Dominguez J; Szász J; Beller C; Howerton C; Jensen L; McClung C; Roebling R; Steiniger-Brach B
    Epilepsia Open; 2021 Sep; 6(3):618-623. PubMed ID: 34265173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study.
    Trinka E; Rocamora R; Chaves J; Moreira J; Ikedo F; Soares-da-Silva P;
    Epilepsia; 2020 Oct; 61(10):2129-2141. PubMed ID: 32944934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.